## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foreword</td>
<td>xxiii</td>
</tr>
<tr>
<td>Preface</td>
<td>xxv</td>
</tr>
<tr>
<td><strong>CHAPTER 1</strong></td>
<td></td>
</tr>
<tr>
<td>Coordinating New Drug Application (NDA) and Patent Portfolio Strategy</td>
<td>1</td>
</tr>
<tr>
<td>I. Introduction</td>
<td>1</td>
</tr>
<tr>
<td>II. A Changing Landscape</td>
<td>2</td>
</tr>
<tr>
<td>A. The Impact of Portfolio Planning</td>
<td>2</td>
</tr>
<tr>
<td>B. Looking Back at the Cliff</td>
<td>3</td>
</tr>
<tr>
<td>III. Strategic Portfolio Planning</td>
<td>6</td>
</tr>
<tr>
<td>A. Enacting a Team-Based Approach</td>
<td>6</td>
</tr>
<tr>
<td>IV. Building the Portfolio</td>
<td>7</td>
</tr>
<tr>
<td>A. Research and Development</td>
<td>7</td>
</tr>
<tr>
<td>B. Cost/Benefit of Filing</td>
<td>9</td>
</tr>
<tr>
<td>C. Timing of Filing</td>
<td>10</td>
</tr>
<tr>
<td>D. Acquisitions</td>
<td>12</td>
</tr>
<tr>
<td>E. Reassessing Existing Portfolios</td>
<td>13</td>
</tr>
<tr>
<td>V. Managing the Portfolio</td>
<td>14</td>
</tr>
<tr>
<td>VI. Utilizing the Portfolio</td>
<td>15</td>
</tr>
<tr>
<td>VII. Conclusion</td>
<td>16</td>
</tr>
<tr>
<td><strong>CHAPTER 2</strong></td>
<td></td>
</tr>
<tr>
<td>Preclinical R&amp;D</td>
<td>17</td>
</tr>
<tr>
<td>I. Lead Compounds</td>
<td>18</td>
</tr>
<tr>
<td>A. Identification</td>
<td>18</td>
</tr>
</tbody>
</table>
CONTENTS

II. Pharmacokinetics 21
   A. Safety and Efficacy 24
   B. Toxicology 26
   C. Drug Supply and Scale-Up 28
III. Summary 34

CHAPTER 3
Preclinical Patent Considerations 35

I. Identifying Intellectual Property (IP) Opportunities and Ensuring Freedom to Operate (FTO) 35
   A. Identifying IP Opportunities 36
   B. Ensuring Freedom to Operate 40
II. Patent Application Filing Strategies 44
   A. Invention and Patent 45
   B. Timing 47
   C. Scope of Offensive and Defensive Filings 50
   D. Optimal Patent Protection 51
III. Conclusion 67

CHAPTER 4
Clinical Trials and Regulatory Considerations 69

I. Introduction 69
   A. Code of Federal Regulations (CFR) 69
II. Drug Development Process 70
   A. Preclinical Stage of Drug Development 71
   B. Clinical Stage of Drug Development 72
   C. Regulatory Stage of Drug Development 73
   D. Commercial Stage of Drug Development 74
III. Types of Clinical Trials 75
   A. Human Pharmacology Studies 75
   B. Therapeutic Exploratory Studies 78
   C. Therapeutic Confirmatory Studies 79
   D. Therapeutic Use Studies 80
   E. Classification According to Phases 81
IV. ICH Guidelines 81
   A. General Principles 82
   B. Regulatory Benefits 82
   C. GCP Guidelines 84
   D. ClinicalTrials.gov 84
V. Summary 84
<table>
<thead>
<tr>
<th>CHAPTER 5</th>
<th>Clinical Trial–Patent Considerations</th>
<th>85</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Introduction</td>
<td>85</td>
<td></td>
</tr>
<tr>
<td>II. Public Use, On Sale, or Otherwise Available to the Public</td>
<td>86</td>
<td></td>
</tr>
<tr>
<td>A. Public Accessibility</td>
<td>87</td>
<td></td>
</tr>
<tr>
<td>B. Commercial Exploitation</td>
<td>92</td>
<td></td>
</tr>
<tr>
<td>C. The On-Sale Bar</td>
<td>93</td>
<td></td>
</tr>
<tr>
<td>D. Experimental Use</td>
<td>95</td>
<td></td>
</tr>
<tr>
<td>III. Government Funding and Disclosure</td>
<td>97</td>
<td></td>
</tr>
<tr>
<td>IV. Expected and Unexpected Results for Patent Considerations</td>
<td>99</td>
<td></td>
</tr>
<tr>
<td>A. Repurposing Compounds</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>B. Rebutting a Prima Facie Case of Obviousness</td>
<td>102</td>
<td></td>
</tr>
<tr>
<td>C. Compliance with 35 U.S.C. § 112, First Paragraph</td>
<td>107</td>
<td></td>
</tr>
<tr>
<td>V. Conclusion</td>
<td>108</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CHAPTER 6</th>
<th>Trademark™ and Nonproprietary Name Considerations</th>
<th>109</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Introduction: The Headache of Pharmaceutical Naming</td>
<td>109</td>
<td></td>
</tr>
<tr>
<td>II. Pharmaceutical Trademarks</td>
<td>110</td>
<td></td>
</tr>
<tr>
<td>A. The USPTO’s Role: The Benefits of Federal Trademark Registration</td>
<td>111</td>
<td></td>
</tr>
<tr>
<td>B. The FDA’s Role: Regulating Direct to Consumer Advertising</td>
<td>112</td>
<td></td>
</tr>
<tr>
<td>C. Considerations in Selecting Pharmaceutical Trademarks</td>
<td>114</td>
<td></td>
</tr>
<tr>
<td>D. The Approval Process for Pharmaceutical Trademarks</td>
<td>127</td>
<td></td>
</tr>
<tr>
<td>III. Nonproprietary Names</td>
<td>135</td>
<td></td>
</tr>
<tr>
<td>A. Selecting Nonproprietary Names</td>
<td>135</td>
<td></td>
</tr>
<tr>
<td>B. USAN Application and Approval Process</td>
<td>138</td>
<td></td>
</tr>
<tr>
<td>IV. Conclusion</td>
<td>139</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CHAPTER 7</th>
<th>Investigational New Drug (IND) and New Drug Applications (NDA)</th>
<th>141</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Introduction</td>
<td>141</td>
<td></td>
</tr>
<tr>
<td>II. Investigational New Drug Applications: Types and Requirements</td>
<td>142</td>
<td></td>
</tr>
<tr>
<td>III. New Drug Applications: Types and Requirements</td>
<td>144</td>
<td></td>
</tr>
<tr>
<td>A. The 505(b)(1) Application</td>
<td>145</td>
<td></td>
</tr>
<tr>
<td>B. The 505(b)(2) Application</td>
<td>149</td>
<td></td>
</tr>
<tr>
<td>C. The FDA Draft Guidance</td>
<td>150</td>
<td></td>
</tr>
</tbody>
</table>
D. The Mechanics of Preparing and Submitting an NDA 160
E. Negotiating the Label 162
F. Changing the Label after Approval: Section 505(o)(4) 166
G. Changing the Label after Approval: Section 506A 167

IV. Prescription Drug User Fee Act 172
V. Conclusion 178

CHAPTER 8
Regulatory Exclusivity 179

I. Regulatory Exclusivity and Requirements 179
A. New Chemical Entities 179
B. New Clinical Investigation 181
C. Orphan Drug 181
D. Pediatric 183
E. Miscellaneous Exclusivity Provisions 184

II. Challenges to Exclusivity Determinations 186
A. Procedural Considerations 186
B. New Chemical Entity Challenges 188
C. New Clinical Data Challenges 195
D. Orphan Drug Challenges 199
E. Pediatric Exclusivity Challenges 202

III. Patent Term Extension 204
A. Background 204
B. Application 204

CHAPTER 9
Overview of the NDA Review Process 209

I. Introduction 209

II. Governance and Guidance Regarding NDA Procedures 210
A. Laws and Regulations Governing NDA Review 210
B. Code of Federal Regulations (C.F.R.) 213

III. NDA Review Policy, Procedure, and Guidance Documents 213
A. CDER's Manual of Policies and Procedures (MaPPs) 213
C. Other FDA Published Guidance 214

IV. Primary Steps of the NDA Pre-Submission Process 216
A. Pre-Submission Meeting to Ensure Application Readiness 216
B. Recommended Contents of Pre-Submission Meeting Request 216
C. Pre-Submission Meeting Participants 217
D. Conducting the Pre-Submission Meeting 218
V. Receiving and Processing the NDA Submission 219
   A. Receipt Marks Beginning of Review 219
   B. Determination of Regulatory Compliance 220
   C. Assessing and Assigning Reviewers 220

VI. Filing Determination and Review Planning Phase 221
   A. Fileability Determination and Start of “Filing Clock” 221
   B. Planning a Review of the Filed Application 222

VII. Conducting the Scientific and Regulatory Review of the NDA 223
   A. The Review Process 224

VIII. Taking Official Action on the Disposition of the NDA 229

IX. Providing Post-Action Feedback to the NDA Applicant/Sponsor 230
   A. Disputes 230

X. Conclusion 231

CHAPTER 10
Orange Book Listable Patents 233

I. Requirements for Orange Book Listing 233

II. Completion of Forms 3542 and 3542a 235
   A. Section 1—General 236
   B. Section 2—Drug Substance (Active Ingredient) 236
   C. Section 3—Drug Product (Composition/Formulation) 237
   D. Section 4—Method of Use 237
   E. Section 5—No Relevant Patents 238
   F. Section 6—Declaration Certification 238

III. Confirming or Obtaining Protective Claim Scope 239
   A. Protecting Approved Indications 239
   B. Challenges to Listings under 21 C.F.R. § 314.53(f) 240
   C. Challenges to Listings under 21 U.S.C. § 355(j) 240
   D. Coordinating Patent Prosecution and Regulatory Strategies and Submissions 240
   E. Non–Orange Book Listable Patent Protection 242
   F. Delisting 243
   G. Nuances of Challenges to Listed Patents 244

CHAPTER 11
Postmarketing Regulatory Requirements and Life Cycle Management 245

I. Postmarketing Regulatory Requirements 245
   A. Mandatory Adverse Drug Experience Monitoring and Reporting 246
   B. Drug Product Labeling 250
   C. Risk Evaluation and Mitigation Strategies 258
### CONTENTS

D. Postmarketing Studies and Clinical Trials 267  
E. Additional Postapproval Regulatory Requirements—Annual Reports 271  

II. Life Cycle Management in the Regulatory Context 273  
A. Postapproval Changes to an NDA 273  
B. Data and Marketing Exclusivities 281  
C. Strategies to Forestall Generic Competition 284  

**CHAPTER 12**  
**Continued Patent Portfolio Development before the Patent Office** 291  

| I. Patent Portfolio Strategies 291  
| A. Approved Products and Indications 292  
| B. Alternative Formulations 296  
| C. New Indications and Target Populations 300  
| D. Combination Compositions and Alternative Dosing Strategies 303  
| II. Patent Prosecution Strategies 305  
| A. Continuing Patent Applications 305  
| B. Reissue Patent 309  
| C. Reexamination Practice 311  
| D. Post Grant Review, Inter Partes Review 315  
| E. Expedited Prosecution 319  
| III. Conclusion 326  

**CHAPTER 13**  
**Acquiring and In-Licensing Pharmaceutical Products: Due Diligence Issues** 327  

| I. Chain of Title/Scope of Rights 327  
| A. Inventorship 328  
| B. Transfer of Intellectual Property Rights to the Company 329  
| C. License and Co-Development Agreements 331  
| D. Formalities in Order 335  
| II. Asset Evaluation 339  
| A. Evaluation Process 339  
| B. Sharing Information with Seller and Licenser 340  
| C. Privilege of Counterparty Communications 341  
| III. Patent Due Diligence 342  
| A. Intellectual Property Rights to Be Transferred 342  
| B. Patents Covering Product 344  

---

```
```

---
Contents

C. Validity 346
D. Patentability Searches 350
E. Freedom to Operate (FTO) 351
F. Design Around Issues 353
G. PTE Decision for Multi-Patent Families 354
H. Life Cycle Management 355
IV. Trademarks 356
   A. Traditional and Nontraditional 357
   B. Validity 358
   C. Scope of Protection 359
   D. Ownership 361
V. Trade Secrets 361
   A. Enforceability 362
   B. Process 363
   C. Know How 363
   D. Valuation 364
VI. Standing to Enforce Intellectual Property Rights 366
   A. Necessary Parties 366
   B. Acquirer Rights 367
VII. Regulatory Considerations 368
   A. PTE Candidates 368
   B. Mapping of Market Exclusivity 369
   C. Timing of Potential ANDA Filings 372

CHAPTER 14
Pre-Litigation Investigations and Due Diligence 375

I. Introduction 375
II. Fact Investigation 375
   A. Document Preservation 375
   B. Invention Story 380
   C. Secondary Considerations 382
   D. Initial Disclosures 384
III. Patent Evaluations 385
   A. Claim Construction 385
   B. Validity/Enforceability 388
   C. Infringement 394
   D. Ownership and Standing 396
IV. Receiving Paragraph IV Notices 397
   A. What to Look For 397
   B. Evaluation of Concerns 400
V. Conclusion 400
CHAPTER 15
Market Entry Business Considerations for Generic Companies 403

I. Brand-Name Drug Markets and Patent Expiry 403
II. First-Filer and Early Entrant Advantage 409
III. Generic Entry’s Effect on Branded and Generic Prices 411
IV. Key Generic Manufacturer Costs 413
V. Competitive Advantage: Prior Experience and Branding 417

CHAPTER 16
Selection of Generic Drug Candidates 419

I. Selection Based on Therapeutic Category 419
II. Selection Based on Markets 420
III. Preparation of a Master List of Potential Products 420
IV. Preparation of Product Profiles 421
V. Circulation of the Product Profiles to a Group of Custodians in the Organization 422
VI. Detailed Cross-Functional Product Evaluation 422
   A. Intellectual Property Management 422
   B. API R&D, API Analytical R&D, and API Manufacturing 425
   C. Formulation R&D, Formulation Analytical R&D, and Formulation Manufacturing 427
   D. Regulatory Affairs 429
   E. Clinical Research and Medical Affairs 430
   F. Availability of Reference Listed Drug (RLD) Samples and REMS: Clinical Research, Medical Affairs, and Purchase and Procurement 431
   G. Business Development, Marketing, Product Strategic, and Overseas Office 432
   H. Putting Together a Business Case 432
   I. Decision Making 434
VII. Other Options 434
VIII. Conclusion 434

CHAPTER 17
Intellectual Property Considerations Related to Generic Products 437

I. Reference Listed Drug Exclusivities 438
   A. New Chemical Entity Exclusivity (Five Years) 440
   B. New Clinical Investigation (or New Indication) Exclusivity (Three Years) 442
   C. Orphan Drug Exclusivity (Seven Years) 443
### Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>D. Pediatric Exclusivity (Six Months)</td>
<td>444</td>
</tr>
<tr>
<td>E. Biologics Price Competition and Innovation Act</td>
<td>446</td>
</tr>
<tr>
<td>II. Identification and Evaluation of Patents on RLDs</td>
<td>448</td>
</tr>
<tr>
<td>A. Review and Analysis of Orange Book and Related Patents</td>
<td>448</td>
</tr>
<tr>
<td>B. Evaluation of Strength/Type of Patent Protection</td>
<td>450</td>
</tr>
<tr>
<td>C. Evaluation of Patent Validity and Enforceability</td>
<td>452</td>
</tr>
<tr>
<td>III. Design-Around Opportunities</td>
<td>454</td>
</tr>
<tr>
<td>A. Prosecution History Estoppel</td>
<td>454</td>
</tr>
<tr>
<td>B. Disclosed “But Not Claimed” Embodiments</td>
<td>454</td>
</tr>
<tr>
<td>C. Section VIII Statements</td>
<td>455</td>
</tr>
<tr>
<td>D. Orange Book Use Codes</td>
<td>456</td>
</tr>
<tr>
<td>CHAPTER 18</td>
<td>459</td>
</tr>
<tr>
<td>Preparation of Noninfringement/Invalidity Legal Opinions</td>
<td></td>
</tr>
<tr>
<td>I. Patent Legal Opinions in Support of an ANDA Product</td>
<td>459</td>
</tr>
<tr>
<td>II. Timing and Logistics of Opinion Preparation</td>
<td>460</td>
</tr>
<tr>
<td>III. Noninfringement versus Invalidity Opinions</td>
<td>461</td>
</tr>
<tr>
<td>IV. Requirements for a Competent Opinion</td>
<td>462</td>
</tr>
<tr>
<td>V. Opinion Format and Content</td>
<td>463</td>
</tr>
<tr>
<td>VI. Elements of a Noninfringement Opinion</td>
<td>464</td>
</tr>
<tr>
<td>VII. Elements of an Invalidity Opinion</td>
<td>468</td>
</tr>
<tr>
<td>VIII. Caveats and Use of the Opinion</td>
<td>474</td>
</tr>
<tr>
<td>CHAPTER 19</td>
<td>475</td>
</tr>
<tr>
<td>Preparing Your ANDA with an Eye towards Approval and Litigation</td>
<td></td>
</tr>
<tr>
<td>I. Introduction</td>
<td>475</td>
</tr>
<tr>
<td>II. Planning to Succeed</td>
<td>476</td>
</tr>
<tr>
<td>III. Pay to Play: User Fees under GDUFA, GDUFA II, and FDARA</td>
<td>477</td>
</tr>
<tr>
<td>A. ANDA Submission Fee</td>
<td>478</td>
</tr>
<tr>
<td>B. Program Fees</td>
<td>479</td>
</tr>
<tr>
<td>C. Facility Fees</td>
<td>479</td>
</tr>
<tr>
<td>D. API-Related Fee</td>
<td>480</td>
</tr>
<tr>
<td>E. Drug Master File (DMF) Fees and Additional Information</td>
<td>480</td>
</tr>
<tr>
<td>IV. The Initial ANDA Filing</td>
<td>481</td>
</tr>
<tr>
<td>A. Paper or Plastic?</td>
<td>481</td>
</tr>
<tr>
<td>B. The ANDA Checklist—Managing Your Modules</td>
<td>482</td>
</tr>
<tr>
<td>V. All Hands on Deck: Filing Your ANDA</td>
<td>491</td>
</tr>
<tr>
<td>A. Start the Clock: Refusal to File and the Paragraph IV Acknowledgment Letter</td>
<td>492</td>
</tr>
<tr>
<td>B. Post-Filing Submissions</td>
<td>493</td>
</tr>
<tr>
<td>VI. Conclusion</td>
<td>498</td>
</tr>
</tbody>
</table>
## CHAPTER 20
### Section VIII Carve-Outs

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Section VIII Statements</td>
<td>499</td>
</tr>
<tr>
<td>II. Use Codes and the New FDA Rules</td>
<td>500</td>
</tr>
<tr>
<td>III. Patent Delisting Disputes</td>
<td>503</td>
</tr>
<tr>
<td>IV. Advantages of a Section VIII Carve-Out for Generic Applicants</td>
<td>504</td>
</tr>
<tr>
<td>V. Carve-Out Labels and Induced Infringement</td>
<td>506</td>
</tr>
</tbody>
</table>

## CHAPTER 21
### Obtaining ANDA Approval and Right to Market

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Exclusivity and Patent Protection for Reference Listed Drugs</td>
<td>511</td>
</tr>
<tr>
<td>A. NDA Exclusivities</td>
<td>512</td>
</tr>
<tr>
<td>B. Enforcement of NDA Exclusivities</td>
<td>514</td>
</tr>
<tr>
<td>C. Patent Protection for NDA-Listed Drugs</td>
<td>514</td>
</tr>
<tr>
<td>II. The ANDA Application Process</td>
<td>517</td>
</tr>
<tr>
<td>A. Litigation Involving ANDAs</td>
<td>518</td>
</tr>
<tr>
<td>B. Certifying to Orange Book–Listed Patents</td>
<td>519</td>
</tr>
<tr>
<td>C. Declaratory Judgment Actions</td>
<td>523</td>
</tr>
<tr>
<td>D. Counterclaims in Hatch-Waxman Cases</td>
<td>527</td>
</tr>
<tr>
<td>III. Approval of ANDAs</td>
<td>530</td>
</tr>
<tr>
<td>A. Final Approval</td>
<td>531</td>
</tr>
<tr>
<td>B. Tentative Approval</td>
<td>534</td>
</tr>
<tr>
<td>C. Delaying ANDA Approvals</td>
<td>536</td>
</tr>
</tbody>
</table>

## CHAPTER 22
### Providing Notice to the NDA Holder

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Introduction</td>
<td>537</td>
</tr>
<tr>
<td>II. Infringing and Noninfringing ANDAs</td>
<td>537</td>
</tr>
<tr>
<td>III. Requirement to Provide Notice</td>
<td>538</td>
</tr>
<tr>
<td>A. ANDA with Method-of-Use Certification</td>
<td>538</td>
</tr>
<tr>
<td>B. ANDA with Paragraph IV Certification</td>
<td>539</td>
</tr>
<tr>
<td>IV. Notice Letters and Exclusivity</td>
<td>541</td>
</tr>
<tr>
<td>V. Disclosure of Contentions</td>
<td>543</td>
</tr>
<tr>
<td>VI. The Notice Letter</td>
<td>543</td>
</tr>
<tr>
<td>A. Plaintiff’s Prefiling Investigation</td>
<td>543</td>
</tr>
<tr>
<td>B. Challenge of Placeholder Notice Letters</td>
<td>545</td>
</tr>
<tr>
<td>C. Resolution of Claims</td>
<td>546</td>
</tr>
<tr>
<td>D. Confidentiality of Notice Letters</td>
<td>547</td>
</tr>
<tr>
<td>E. Damages Issues</td>
<td>549</td>
</tr>
<tr>
<td>VII. Conclusion</td>
<td>552</td>
</tr>
</tbody>
</table>
CHAPTER 23
Evaluating Scenarios for Launch, Including Marketing and Manufacturing Developments  553

I. Determining Launch Date  553
   A. At-Risk Launch Scenarios  554
   B. Multiple First-Filers  555
   C. PLAIRs  556
II. Forfeiture Scenarios  557
   A. Failure to Market  558
   B. Withdrawal of Application  560
   C. Amendment of Certification  560
   D. Failure to Obtain Tentative Approval  562
   E. Agreement with Other Applicant, Listed Drug Application Holder, or Patent Owner  562
   F. Expiration of All Patents  562
III. De Facto Exclusivity Longer Than 180 Days  563
IV. Settlement Scenarios  563
V. Licensing Scenarios  564

CHAPTER 24
Interplay between Inter Partes Review (IPR) and ANDA Litigation  567

I. Background  567
II. Hatch-Waxman ANDA Litigation:
   Use of IPR in the ANDA Context  569
III. Timing of IPR Filing versus ANDA Filing  570
IV. Drop in ANDA Litigation in 2016  572
V. ANDA Filers May Elect to File in Advance of P-IV Filing  577
VI. Factors to Consider before Initiating an IPR/ANDA Interplay  580

CHAPTER 25
Citizen Petitions  585

I. Definition  585
II. The 505(q) Citizen Petition  586
   A. Notable Exceptions  589
III. Specific Topics in Past Citizen Petitions  589
   A. To Prevent Section VIII Label Carve-Outs  589
   B. To Require a Split Patent Certification or Recertification  593
   C. To Impose a Second 30-Month Stay  597
   D. To Designate a New Reference Standard  600
   E. To Require a New Bioequivalence or Other Clinical Study  602
F. To Deem That a First Applicant Has Forfeited Any 180-Day Exclusivity 605
G. To Require That a Drug Product Be Marketed in Connection with a Particular Device 609

CHAPTER 26
Expedited Regulatory Pathways 613

I. Accelerated Approval 615
   A. Benefits of the Accelerated Approval Program 615
   B. Eligibility for the Accelerated Approval Program 617
   C. Conditions of Accelerated Approval 620
II. Fast Track 621
   A. Benefits of the Fast Track Program 621
   B. Eligibility for the Fast Track Program 622
   C. Designation Request Procedure 624
III. Breakthrough Therapies 625
   A. Benefits of the Breakthrough Therapies Program 625
   B. Eligibility for the Breakthrough Therapies Program 627
   C. Designation Request Procedure 629
IV. Priority Review 631
   A. Benefits of the Priority Review Program 631
   B. Eligibility for the Priority Review Program 632
   C. Request Procedure 633

CHAPTER 27
REMS 101 for ANDA Litigators and Counselors 635

I. Introduction 635
II. REMS 636
   A. Risk Evaluation and Mitigation? Strategy (REMS) Defined 636
   B. Different Components of a REMS Program 637
   C. Individual and Shared REMS 641
III. Examples of REMS-Related Proceedings 642
   A. Litigation in Federal Court 642
   B. Proceedings at the Patent Trial and Appeal Board (PTAB) 646
   C. Citizen Petitions at FDA 650
   D. Waiver of SSS Requests at FDA (and Lawsuits against FDA under the APA) 653
IV. Conclusion 655
CHAPTER 28
Regulatory Compliance: Inspections and Their Consequences 657

I. Introduction 657
II. Inspections 658
   A. cGMP Inspections 659
   B. Pre-Approval Inspections 661
   C. Active Pharmaceutical Ingredients 663
   D. Foreign Inspections 664
III. Outcome of Inspections and Other Regulatory Actions 665
   A. Inspection Classification Codes for Facility 665
   B. Agency Actions, Including Enforcement 667
IV. A Cautionary Compliance Tale—Ranbaxy 678
V. Conclusion 684

CHAPTER 29
Biologic Drugs and the Biologics Price Competition and Innovation Act 685

I. Introduction 685
II. The Market for Biological Products 686
   A. What Is a “Biologic”? 686
   B. Making Biological Products versus Small-Molecule Drugs 687
III. Federal Regulation of Biologics 688
   A. “Biosimilar” Drugs and “Interchangeable” Drugs 690
   B. Exclusivity Periods 692
   C. Challenges over Data Exclusivity 695
   D. The Continuing Role of Patent Protection under the BPCIA 698
IV. Patent Litigation under the BPCIA 698
   A. Exchange of Information 699
   B. Patent Resolution Negotiations 701
   C. Immediate Patent Infringement Action 702
   D. Declaratory Judgment Suits and Preliminary Injunctions under the BPCIA 704
V. Conclusion 705

CHAPTER 30
Pharmaceutical Regulation and Approval in Foreign Countries 707

I. Introduction 707
II. Australia—Pharmaceutical Regulatory Approval Strategy 707
   A. Introduction 707
   B. Australian Register of Therapeutic Goods 708
   C. Registration of Prescription Medicines 712
## CONTENTS

D. Data Exclusivity 728  
E. Orphan Drug Program 729  
F. Clinical Trials 731  
G. Marketing and Advertising of Therapeutic Goods 734  
H. Pharmaceutical Benefits Scheme (PBS) 739  
I. Intellectual Property Considerations 747  

III. Brazilian Drug Approval Considerations 764  
A. Patent Portfolio 765  
B. Clinical Trials 766  
C. Strategies 772  

IV. Canadian Drug Approval Considerations 775  
A. Introduction on Coordinating NDS/ANDS Filing Strategy in Canada 775  
B. Pre-Regulatory Submission Phase 776  
C. Naming the Compound—Trademark and Nonproprietary Name Issues 786  
D. Regulatory Approval Phase 788  
E. Regulatory Exclusivity 800  
F. Patented Medicine Considerations in Canada 802  
G. Marketing Considerations 823  
H. Trademark Considerations 825  
I. Conclusion 826  

V. The United Kingdom and European Union Approval Considerations 826  
A. Introduction to the European Union Legal Structure 827  
B. Patents in the European Union 828  
C. Regulation of Clinical Trials in the European Union 841  
D. Authorization of Medicinal Products for Human Use 851  
E. Pharmaceutical Trademarks 885  
F. Regulatory Exclusivity for Medicinal Products in the EU 898  
G. Supplementary Protection Certificates 913  
H. Post-Authorization Issues 927  

VI. Japanese Drug Approval Considerations 951  
A. Building a Drug and Patent Portfolio: Considerations for Innovators 951  
B. Considerations for Generic Drug Companies 961  
C. Drug Pricing in Japan 966  

## INDEX 969